{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:06:42Z","timestamp":1772921202809,"version":"3.50.1"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.2169\/internalmedicine.5656-25","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:09:05Z","timestamp":1753913345000},"page":"703-707","source":"Crossref","is-referenced-by-count":1,"title":["Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome"],"prefix":"10.2169","volume":"65","author":[{"given":"Chiaki","family":"Kubara","sequence":"first","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Tochigi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayasu","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting <i>FLT3<\/i> mutations in AML: review of current knowledge and evidence. Leukemia 33: 299-312, 2019.","DOI":"10.1038\/s41375-018-0357-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev 6: e4, 2012.","DOI":"10.4081\/oncol.2012.e8"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Gale RE, Green C, Allen C, et al. The impact of <i>FLT3<\/i> internal tandem duplication mutant level, number, size, and interaction with <i>NPM1<\/i> mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111: 2776-2784, 2008.","DOI":"10.1182\/blood-2007-08-109090"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of <i>FLT3<\/i>-TKD mutations in AML: the combination matters - an analysis of 3082 patients. Blood 111: 2527-2537, 2008.","DOI":"10.1182\/blood-2007-05-091215"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory <i>FLT3<\/i>-mutated AML. N Engl J Med 381: 1728-1740, 2019.","DOI":"10.1056\/NEJMoa1902688"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory <i>FLT3<\/i>-ITD acute myeloid leukemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20: 984-997, 2019.","DOI":"10.1016\/S1470-2045(19)30150-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Erba HP, Montesinos P, Kim HJ, et al.; the QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with <i>FLT3<\/i>-internal-tandem-duplication-positive acute myeloid leukemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401: 1571-1583, 2023.","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther 16: 991-1001, 2017.","DOI":"10.1158\/1535-7163.MCT-16-0876"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123: 2777-2782, 2014.","DOI":"10.1182\/blood-2013-10-512640"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fathi AT, Stein EM, DiNardo CD, Levis MJ, Montesinos P, DeBotton S. Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. Am J Hematol 96: 735-746, 2021.","DOI":"10.1002\/ajh.26142"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Erba H, Wang E, Issa G, et al. AML-475 activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed\/refractory NPM1-mutated AML. Clin Lymphoma Myeloma Leuk 23: S304-S305, 2023.","DOI":"10.1016\/S2152-2650(23)01067-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C\/EBP\u03b1 expression. Blood 103: 1883-1890, 2004.","DOI":"10.1182\/blood-2003-06-1978"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory <i>FLT3<\/i>-mutated acute myeloid leukemia. Blood Adv 3: 1581-1585, 2019.","DOI":"10.1182\/bloodadvances.2018029496"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nybakken GE, Canaani J, Roy D, et al. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia 30: 1422-1425, 2015.","DOI":"10.1038\/leu.2015.320"},{"key":"15","unstructured":"15. Issa GC, Stein EM, DiNardo CD. How I treat: differentiation therapy in acute myeloid leukemia. Blood 143: 1049-1061, 2024."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kondo T, Onozawa M, Fujisawa S, et al. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of <i>FLT3<\/i>-ITD-positive AML treated with gilteritinib. Hematology 26: 256-260, 2021.","DOI":"10.1080\/16078454.2021.1889111"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Dugan J, Jain N, Irons C, Sharma P, Sediqe S, Hejal R. Differentiation syndrome after gilteritinib: a tricky mimicker of sepsis. Chest 160: 877, 2021.","DOI":"10.1016\/j.chest.2021.07.820"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Woods AC, Norsworthy KJ. Differentiation syndrome in acute leukemia: APL and beyond. Cancers 15: 4767, 2023.","DOI":"10.3390\/cancers15194767"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5656-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:45:44Z","timestamp":1772855144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5656-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5656-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"5656-25"}}